Inotuzumab Ozogamicin in Clinical Development for Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma
B cell acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) frequently express CD19, CD20 and CD22 on the cell surfaces. Immunotherapeutic agents including antibodies and chimeric antigen receptor T cells are widely studied in clinical trials. Several antibody-drug conjugates (ADC) have been approved for clinical use (gemtuzumab ozogamicin in acute myeloid leukemia and brentuximab vedotin in Hodgkin lymphoma as well as CD30+ anaplastic large cell lymphoma). Inotuzumab ozogamicin (INO), a CD22 antibody conjugated with calicheamicin is one of the newest ADCs. INO has been approved for treatment of relapsed /refractory B cell precursor ALL. Multiple ongoing trials are evaluating its role in the relapsed /refractory B cell NHL. This review summarized recent development in INO applications for ALL and NHL.
Aujla, A., Aujla, R., & Liu, D. (2019). Inotuzumab Ozogamicin in Clinical Development for Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma. Biomarker Research, 7, 9. https://doi.org/10.1186/s40364-019-0160-4